The company Genome & Company (CEO Bae Ji-soo, Han-soo Park) plans to release key data on the phase 2 clinical trial of ‘GEN-001’ for gastric cancer at the “American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024)” scheduled for January 2024.
The ASCO GI Symposium is one of the internationally recognized conferences in the field of gastrointestinal cancers, where scholars and experts gather to discuss the latest research findings and treatment strategies.
Genome & Company’s presentation will include data from the phase 2 clinical trial of ‘GEN-001’ for gastric cancer collected up to the time of the ASCO GI presentation. The phase 2 trial aimed to recruit 42 patients for ‘GEN-001’ for gastric cancer, and the company plans to disclose key data on safety and efficacy.
‘GEN-001’ is an immune-oncology therapy based on the microbiome, and it is undergoing phase 2 clinical trials for gastric cancer in combination with Bavencio (generic name: avelumab) from Merck KGaA, Germany. As developing a new treatment for patients with gastric cancer who have failed standard treatments beyond the second line is crucial, the company aims to demonstrate superior efficacy beyond the limitations of existing immune-oncology agents through the phase 2 clinical trial of ‘GEN-001,’ according to company officials.
Bae Ji-soo, CEO of Genome & Company, stated, “The presentation at ASCO GI holds significant importance in proving the anti-cancer efficacy of the microbiome-based immune-oncology therapy GEN-001.” He added, “In the current situation of the volatile financial market and the prolonged stagnation of the bioindustry, we hope this presentation can be a positive signal.”
Genome & Company is located in Pangyo Techno Valley, a bio-cluster in South Korea, and it went public on the KOSDAQ market in 2020.
For inquiries and connections with Korean tech companies mentioned in this article, contact us at [email protected]. We’re here to facilitate valuable partnerships.
What’s your thoughts?